+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumors: a meta-analysis



Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumors: a meta-analysis



World Journal of Surgical Oncology 12: 71



The postulated relationship between KIT/PDGFRA mutations and their prognostic value in gastrointestinal stromal tumors (GISTs) has generated intense attention during the past decade, despite the fact that a great deal of studies have been conducted on this subject. To provide a strong quantitative estimate of this postulated relationship, we carried out a meta-analysis which combined, compared, and summarized the results of existing relevant studies. Studies were identified by searching databases and reviewing citations in relevant articles. Of 48 potentially relevant studies, we combined individual patient data from 18 studies which involved 1,487 patients with GISTs, by which we made a comparison between the positive KIT mutation subgroup and the negative KIT mutation subgroup (PDGFRA mutation and wild type). We tabulated and analyzed the patient characteristics from each study, including general information such as age and gender, histopathological parameters, and clinical follow-up outcomes. KIT mutations, compared with PDGFRA mutations and wild type, showed a marked increased risk not only for tumor size (>5 cm) but also for higher mitotic activity (>5), suggesting that KIT mutations significantly correlated with the National Comprehensive Cancer Network (NCCN) high risk or National Institutes of Health (NIH) high risk (1.74 (95% CI, 1.20 to 2.53) and 2.00 (95% CI, 1.08 to 3.68), respectively). Moreover, higher recurrence and metastasis was observed in GISTs with KIT mutations, revealing its closer correlation with clinical malignant risk (P<0.001 for each, with odds ratio (OR) of 2.06 (95%, 1.37 to 3.11) and 2.77 (95%, 1.64 to 4.67), respectively). High risk or malignant GISTs with KIT mutations had a significantly poorer prognosis, as measured by 3-year overall survival, compared to those with PDGFRA mutations and wild type (0.47 (95% CI, 0.25 to 0.90)). KIT mutations, compared with PDGFRA mutations and wild type, represent a poorer prognostic marker in high risk or malignant GISTs.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 055213525

Download citation: RISBibTeXText

PMID: 24674052

DOI: 10.1186/1477-7819-12-71


Related references

Prognostic relevance of KIT and PDGFRA mutations in gastrointestinal stromal tumors. Anticancer Research 30(6): 2407-2414, 2010

KIT and PDGFRA mutations and PDGFRA immunostaining in gastrointestinal stromal tumors. Molecular Medicine Reports 4(1): 3-8, 2011

Chromosome copy number changes carry prognostic information independent of KIT/PDGFRA point mutations in gastrointestinal stromal tumors. Bmc Medicine 8: 26, 2010

Intratumoral KIT mutational heterogeneity and recurrent KIT/ PDGFRA mutations in KIT/PDGFRA wild-type gastrointestinal stromal tumors. Oncotarget 7(21): 30241-9, 2016

Status and clinical analysis of c-kit and PDGFRA mutations in the gastrointestinal stromal tumors. Zhonghua Wei Chang Wai Ke Za Zhi 11(4): 371-375, 2008

Diagnostic morphological features of PDGFRA-mutated gastrointestinal stromal tumors: molecular genetic and histologic analysis of 60 cases of gastric gastrointestinal stromal tumors. Annals of Diagnostic Pathology 11(1): 27-33, 2007

Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis. Journal of Gastrointestinal and Liver Diseases 22(4): 413-418, 2013

PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299(5607): 708-710, 2003

Different types of KIT and PDGFRA mutations in gastrointestinal stromal tumors. 2007

KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs). Seminars in Diagnostic Pathology 23(2): 91, 2006

Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial. JAMA Oncology 3(5): 602-609, 2017

Coexisting C-KIT and PDGFRA mutations in gastrointestinal stromal tumors (GIST). 2008

C-kit and PDGFRA mutations in 60 cases of gastrointestinal stromal tumors (GISTs). Beijing Da Xue Xue Bao. Yi Xue Ban 37(3): 320-324, 2005

Microfluidic deletion/insertion analysis for rapid screening of KIT and PDGFRA mutations in CD117-positive gastrointestinal stromal tumors: diagnostic applications and report of a new KIT mutation. Journal of Molecular Diagnostics 9(2): 151-157, 2007

Differentially expressed proteins in gastrointestinal stromal tumors with KIT and PDGFRA mutations. Proteomics 6(4): 1151-1157, 2006